Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients (AIRPORT-MPN)
Myeloproliferative Neoplasm (MPN), Essential Thrombocythemia (ET), JAK2 Mutation
About this trial
This is an interventional prevention trial for Myeloproliferative Neoplasm (MPN)
Eligibility Criteria
Inclusion Criteria:
- Male or female subjects aged 18 years or older,
- Confirmed diagnosis of PV, JAK2ET or JAK2 pre-fibrotic MF, per local clinical definitions
- Able and willing to comply with study procedures and follow-up examinations contained within the written consent form
Exclusion Criteria:
- Known allergy to apixaban or aspirin,
- Another need for anticoagulation or specific anti-platelet therapy,
- Contraindication to thromboprophylaxis (which would specifically include but not be limited to platelets less than 50x10^9/L and acquired Von Willebrand disease),
- Current pregnancy or breast-feeding,
- Renal dysfunction (Creatine Clearance <25 mL/min),
- Known liver disease
- Currently on any medication with a known interaction to apixaban
- Unwilling to use an effective means of contraception for women of childbearing potential
- Overtly fibrotic myelofibrosis
- Myelodysplastic/myeloproliferative neoplasms
Sites / Locations
- The Ottawa Hospital
Arms of the Study
Arm 1
Arm 2
Active Comparator
Experimental
Aspirin and cytoreductive therapy (if applicable)
Apixaban and cytoreductive therapy (if applicable)
Patients who are randomized to this group will take a low-dose aspirin 81mg pill once per day (standard-of-care) for at least 6 months along with cytoreductive therapy, if applicable. Patients will then be treated and followed up as per standard of care at the discretion of his or her treating physician after the completion of the study.
Patients who are randomized to this group will receive apixaban 2.5mg twice daily for at least 6 months along with standard intervention, cytoreductive therapy, if applicable. Patients will then be treated and followed up as per standard of care at the discretion of their treating physician after the completion of the study.